Global Breakthrough: Treatment Approved for Narcolepsy
The Ministry of Health has approved, for the first time in the world, a new oral medication for type 1 narcolepsy, developed by Takeda. The drug, Oveporexton, acts on orexin receptors in the brain and addresses the disease mechanism. The approval was based on two Phase 3 trials showing improved alertness, reduced cataplexy attacks, and better quality of life. Common side effects: insomnia and urinary urgency.
The Ministry of Health has approved, for the first time in the world, a new oral medication for type 1 narcolepsy, a rare neurological disorder causing sudden sleep attacks. The drug, developed by Takeda and named Oveporexton, works differently from existing treatments: it activates orexin receptors in the brain, aiming to restore the wakefulness mechanism to normal function. The approval was based on two international Phase 3 trials, which found significant improvement in daytime alertness, reduction in cataplexy attacks (sudden loss of muscle tone), and improved quality of life. Common side effects were insomnia and urinary urgency. Experts view the approval as a turning point, as it marks a shift from treating symptoms to treating the disease mechanism itself. However, additional clinical confirmation after the start of use is still required to validate the results.